IRIS
ASCIERTO, PAOLO ANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.088
NA - Nord America 1.059
EU - Europa 998
SA - Sud America 176
AF - Africa 73
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 3
Totale 5.407
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 2.315
US - Stati Uniti d'America 918
RU - Federazione Russa 315
CN - Cina 238
IT - Italia 208
VN - Vietnam 198
HK - Hong Kong 129
BR - Brasile 123
DE - Germania 106
IN - India 67
GB - Regno Unito 64
CA - Canada 58
NL - Olanda 58
UA - Ucraina 56
MX - Messico 55
FI - Finlandia 28
FR - Francia 23
AR - Argentina 22
ZA - Sudafrica 17
PL - Polonia 16
ES - Italia 15
IQ - Iraq 14
SE - Svezia 13
CH - Svizzera 12
JP - Giappone 12
IE - Irlanda 11
KR - Corea 11
CI - Costa d'Avorio 9
MY - Malesia 9
TR - Turchia 9
ID - Indonesia 8
PK - Pakistan 8
PY - Paraguay 8
BD - Bangladesh 7
BG - Bulgaria 7
IL - Israele 7
AE - Emirati Arabi Uniti 6
AT - Austria 6
AZ - Azerbaigian 5
CZ - Repubblica Ceca 5
DO - Repubblica Dominicana 5
EG - Egitto 5
LT - Lituania 5
VE - Venezuela 5
AL - Albania 4
BY - Bielorussia 4
CL - Cile 4
EC - Ecuador 4
EE - Estonia 4
PT - Portogallo 4
SA - Arabia Saudita 4
AD - Andorra 3
AM - Armenia 3
AU - Australia 3
BE - Belgio 3
CO - Colombia 3
CR - Costa Rica 3
CY - Cipro 3
GA - Gabon 3
KE - Kenya 3
LV - Lettonia 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
PE - Perù 3
PR - Porto Rico 3
PS - Palestinian Territory 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
SY - Repubblica araba siriana 3
TH - Thailandia 3
TW - Taiwan 3
CG - Congo 2
CM - Camerun 2
CW - ???statistics.table.value.countryCode.CW??? 2
DZ - Algeria 2
GF - Guiana Francese 2
GM - Gambi 2
GR - Grecia 2
GT - Guatemala 2
HN - Honduras 2
HR - Croazia 2
HU - Ungheria 2
IR - Iran 2
IS - Islanda 2
JM - Giamaica 2
JO - Giordania 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LB - Libano 2
MA - Marocco 2
ME - Montenegro 2
ML - Mali 2
MW - Malawi 2
NG - Nigeria 2
NI - Nicaragua 2
NP - Nepal 2
PA - Panama 2
PH - Filippine 2
RO - Romania 2
RW - Ruanda 2
Totale 5.362
Salva come PNG Salva come JPEG
Città #
Singapore 625
Hong Kong 129
Ashburn 120
Moscow 74
Hefei 66
Naples 64
Beijing 63
Los Angeles 63
Ho Chi Minh City 55
Hanoi 52
Amsterdam 47
Santa Clara 47
Mexico City 42
Chandler 41
New York 31
Orem 27
Dallas 26
Munich 25
Buffalo 24
Chicago 23
São Paulo 23
Montreal 20
Jacksonville 18
Toronto 18
Milan 17
Boston 15
Millbury 14
Napoli 14
Seattle 13
Da Nang 12
Denver 12
Rome 12
Warsaw 12
Haiphong 11
Johannesburg 11
Redondo Beach 11
Stockholm 11
Tokyo 11
Turku 11
Wilmington 11
Ann Arbor 10
Seoul 10
Woodbridge 10
London 9
Princeton 9
Shanghai 9
Biên Hòa 8
Brooklyn 8
Kuala Lumpur 8
Mumbai 8
Poplar 8
Boardman 7
Frankfurt am Main 7
Ankara 6
Atlanta 6
Phoenix 6
Salt Lake City 6
Sofia 6
The Dalles 6
Cairo 5
Changsha 5
Chennai 5
Helsinki 5
Kochi 5
Lawrence 5
Manchester 5
Nanjing 5
Quảng Ngãi 5
Santo Domingo 5
Tampa 5
Thái Nguyên 5
Asunción 4
Baghdad 4
Baku 4
Calgary 4
Council Bluffs 4
Des Moines 4
Dong Ket 4
Elk Grove Village 4
Falkenstein 4
Houston 4
Hải Dương 4
Lahore 4
Lappeenranta 4
Miami 4
Nuremberg 4
Palermo 4
Paris 4
Sant'Antimo 4
Tianjin 4
Vancouver 4
Xi'an 4
Zurich 4
Bismarck 3
Brussels 3
Cape Town 3
Carouge 3
Charlotte 3
Ciudad del Este 3
Dublin 3
Totale 2.237
Salva come PNG Salva come JPEG
Nome #
Durability of Humoral Immune Responses to SARS-CoV-2 in Citizens of Ariano Irpino (Campania, Italy): A Longitudinal Observational Study With an 11.5-Month Follow-Up 214
Integrated genomics identifies MiR-181/TFAM pathway as a critical driver of drug resistance in melanoma 168
Innate Immune Cells in Melanoma: Implications for Immunotherapy 141
FKBP51s signature in peripheral blood mononuclear cells of melanoma patients as a possible predictive factor for immunotherapy 134
Seroprevalence of SARS-CoV-2-specific antibodies in the town of Ariano Irpino (Avellino, Campania, Italy): A population-based study 133
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial 120
Combinatorial immune checkpoint blockade increases myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1β and interleukin-6: biochemical implications in cardio-immuno-oncology 102
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial 102
PD-L1+ neutrophils as novel biomarkers for stage IV melanoma patients treated with nivolumab 102
Vein wall thickness and severity of pulmonary involvement due to sars n-cov2 virus infection 101
Electrochemotherapy as "new standard of care" treatment for cutaneous Kaposi's sarcoma 98
May the analysis of 1918 influenza pandemic give hints to imagine the possible magnitude of Corona Virus Disease-2019 (COVID-19)? 95
Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents 93
Severe protracted intestinal cryptosporidiosis associated with interferon g deficiency: pediatric case report. 93
Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells 87
The Use of Tocilizumab in Patients with COVID-19: A Systematic Review, Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Studies 87
Clinical outcome prediction in COVID-19 patients by lymphocyte subsets analysis and monocytes’ iTNF-α expression 85
Melanoma-derived soluble mediators modulate neutrophil biological properties and the release of neutrophil extracellular traps 84
The clinical and translational research activities at the INT – IRCCS “Fondazione Pascale” cancer center (Naples, Italy) during the COVID-19 pandemic 81
HHV-8 prevalence, immunosuppression and Kaposi’s sarcoma in South Italy 75
NEMO-binding domain peptide inhibits proliferation of human melanoma cells. 58
MDM2 SNP309 and p53 Arg72Pro in cutaneous melanoma: association between SNP309 GG genotype and tumor Breslow thickness. 57
Complete atrioventricular block in a patient with intracardiac metastases from malignant melanoma 50
Expression of the anti-apoptotic protein BAG3 in human melanomas. 44
Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: A retropective study 44
Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced Merkel Cell Carcinoma 31
Emerging therapeutics for melanoma 26
Prognostic value of serum VEGF in melanoma patients: a pilot study 24
The role of BRAF V600 mutation in melanoma 23
Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma 23
Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4(+)CD25(++)Foxp3(+) regulatory T-cells in advanced melanoma patients 22
Combination therapy: the next opportunity and challenge of medicine 18
Molecular alterations at chromosome 9p21 in melanocytic naevi and melanoma 18
When rarity meets thoracic cancers: a narrative review from ITMIG 2024 18
Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy 17
Survey of the impact of BOLT-trial data on oncologists’ and dermatologists’ decision-making in treating patients with locally advanced basal cell carcinoma 17
Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-alpha in advanced malignant melanoma 17
Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery 16
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma 16
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial 16
Use of artificial intelligence chatbots in clinical management of immune-related adverse events 16
Sentinel lymph node biopsy does not change melanoma-specific survival among patients with Breslow thickness greater than four millimeters 15
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial 15
Results of COLUMBUS Part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma 15
Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy 15
Radiazioni cosmiche 15
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma 15
Operational classification of cutaneous squamous cell carcinomas based on unsupervised clustering of real cases by experts 15
Hedgehog Inhibitors Beyond Clinical Complete Response in Basal Cell Carcinoma: Should I Stop or Should I Go? 15
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases 15
Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma 14
Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC) 14
Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma 14
Serial detection of circulating tumour cells by reverse transcriptase-polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma 14
Molecular Pathogenesis of Melanoma: Established and Novel Pathways 14
Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma 14
Quality-of-life (QoL) in COLUMBUS part 1: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in braf-mutant melanoma 14
Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice 14
Efficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers 14
Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti-PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations 14
The susceptibility CDKN2 locus may have a role on prognosis of melanoma patients 14
Combination therapy: the next opportunity and challenge of medicine 14
Avelumab in European patients (pts) with metastatic Merkel cell carcinoma (mMCC): Experience from an ad-hoc expanded access program (EAP) 13
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy Three-Year Follow-up of a Randomized Phase 3 Trial 13
Where Reflectance Confocal Microscopy Provides the Greatest Benefit for Diagnosing Skin Cancers: The Experience of the National Cancer Institute of Naples 13
Development of muscle spasm during Vismodegib treatment and the effect of treatment interruptions: exploratory analyses from the STEVIE study 13
Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors 13
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial 13
Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1 mg/kg + ipilimumab 3 mg/kg expansion from CheckMate 032 13
Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma 13
The features and management of acquired resistance to PD1-based therapy in metastatic melanoma 13
Health Economic Consequences Associated With COVID-19-Related Delay in Melanoma Diagnosis in Europe 13
Melanoma pathophysiology and drug targets 13
CD73 as biomarker of advanced melanoma response to immunotherapy 13
Quality-of-Life (QoL) in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma 13
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial 12
Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511) 12
Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032 12
Pegylated arginine deiminase treatment of patients with metastatic melanoma: Results from phase I and II studies 12
CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy 12
Efficacy and safety of ‘Second Adjuvant’ therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy 12
Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Updated results from a phase 3 trial (CheckMate 238) 12
A plain language summary of the 7-year update from part 1 of the COLUMBUS study: encorafenib and binimetinib for people with BRAF V600-mutant melanoma 12
Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge 12
A plain language summary of POLARIS: a study to look at different doses of encorafenib plus binimetinib for people with BRAF V600-mutant melanoma with brain metastasis 12
IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab 12
OUTCOMES FOLLOWING CESSATION OF BRAF +/- MEK INHIBITION AFTER ACHIEVING COMPLETE RESPONSE IN BRAF MUTANT ADVANCED MELANOMA 12
Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations 12
Overall Survival (OS) in COLUMBUS: A Phase-III-Study with Encorafenib (ENCO) plus Binimetinib (BINI) versus Vemurafenib (VEM) or ENCO in BRAF mutant Melanoma 12
Real-World efficiency of pembrolizumab in metastatic melanoma patients following adjuvant anti-PD1 treatment 11
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab 11
Defining the critical hurdles in cancer immunotherapy 11
Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study 11
Evaluation of Sonidegib Cytoreductive Activity in Locally Advanced Basal Cell Carcinoma Treatment 11
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma 11
Il melanoma maligno quale modello di studio 11
Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma 11
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium 11
The MITF/mir-579-3p regulatory axis dictates BRAF-mutated melanoma cell fate in response to MAPK inhibitors 11
Immunotherapy followed by cetuximab in locally advanced/metastatic cutaneous squamous cell carcinomas: the I-TACKLE trial 11
Totale 3.527
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.469
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.469
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202126 0 0 0 0 0 2 3 0 7 3 7 4
2021/2022204 0 4 0 1 1 3 4 14 127 8 14 28
2022/2023114 14 5 3 5 16 8 0 11 11 18 7 16
2023/2024136 9 18 22 16 6 11 1 17 2 2 17 15
2024/2025810 42 31 11 16 32 51 81 49 73 85 266 73
2025/20264.628 161 133 204 692 2.891 547 0 0 0 0 0 0
Totale 6.050